Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled iloprost versus placebo in pulmonary hypertension secondary to chronic obstructive pulmonary disease
2011-003310-17Phase 2Completed
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Sep 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH) comparing Inhaled iloprost with Placebo (2 arms). Primary endpoint: Change in exercise endurance time. Started Sep 2011; status: completed.
02
Drugs
iloprost
03
Conditions
Pulmonary hypertension associated with chronic obstructive pulmonary disease (COPD-PH)
Beyond the preview
Go deeper on 2011-003310-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003310-17.